Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer

NCT03667482 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Cancer
Recurrent Head and Neck Squamous Cell Cancer
Metastatic Head and Neck Squamous Cell Cancer

Interventions

DRUG: Cabozantinib
DRUG: Cetuximab

Sponsor

Memorial Sloan Kettering Cancer Center